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Clinical efficacy of anticancer chemotherapies is dramatically hampered by multidrug resistance (MDR) dependent on inherited
traits, acquired defence against toxins, and adaptive mechanisms mounting in tumours. There is overwhelming evidence that
molecular events leading to MDR are regulated by redox mechanisms. For example, chemotherapeutics which overrun the first
obstacle of redox-regulated cellular uptake channels (MDR1, MDR2, andMDR3) induce a concerted action of phase I/II metabolic
enzymes with a temporal redox-regulated axis. This results in rapid metabolic transformation and elimination of a toxin. This
metabolic axis is tightly interconnected with the inducible Nrf2-linked pathway, a key switch-on mechanism for upregulation
of endogenous antioxidant enzymes and detoxifying systems. As a result, chemotherapeutics and cytotoxic by-products of their
metabolism (ROS, hydroperoxides, and aldehydes) are inactivated and MDR occurs. On the other hand, tumour cells are capable
of mounting an adaptive antioxidant response against ROS produced by chemotherapeutics and host immune cells. The multiple
redox-dependent mechanisms involved in MDR prompted suggesting redox-active drugs (antioxidants and prooxidants) or
inhibitors of inducible antioxidant defence as a novel approach to diminish MDR. Pitfalls and progress in this direction are
discussed.
1. Introduction
It is commonknowledge thatmultiple drug resistance (MDR)
has crucial negative impact on the clinical outcomes of con-
ventional cytotoxic anticancer therapies and of those based
on specific drugs targeting molecular pathways implicated
in cancer cell functions and survival strategies. Since the
discovery of the first ATP-binding cassette (ABC) trans-
porter P-glycoprotein (P-gp), ABC drug transporters have
become targets for improving anticancer chemotherapy. Up
to now, more than 49 different ABC transporters have been
found and cloned [1]. A majority of MDR modulators or
reversals are themselves substrates of the transporters that
compete with anticancer agents for the efflux from tumour
cells [2]. Frustrating the great expectations raised, ABC
transporter/modulators/reversals proved to have insufficient
clinical efficacy and very high toxicity. Novel “biological”
approaches have been recently developed in laboratory
to modulate ABC transporter-mediated MDR, including a
monoclonal antibody that binds specifically to P-gp, thus sup-
pressing drug transport, small interfering RNA technology
to decrease the expression of ABCB1, antisense oligonucleot-
ides, and agents attenuating P-gp transcription [3]. Though
very promising, these “biologicals” are still lacking clinical
proof-of-concept data.
In any case, the evident and numerous adverse effects of
MDR modulators stimulated additional studies on physio-
logical role(s) of MDR in the human organism. It has been
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reported that MDR relies not exclusively on transporting
systems for drug uptake and efflux, but also on intracellular
drug metabolism and DNA damage [4]. Transporting and
metabolic systems definingMDR are expressed in the major-
ity of normal cells, are essential for nutrients uptake and
metabolites efflux, and play a vital role in protecting cells
against xenobiotics. Hence, harsh inhibition of a functionally
essential mechanism results in general intoxication.
To gain protection against foreign invasions andmaintain
homeostasis, the human organism employs several types of
physical, chemical, and biological defence systems. For exam-
ple, skin and other lining epitheliamechanically prevent inva-
sion of relatively large organic and inorganic particles. The
immune system has been evolved to fight cellular invaders
and high-molecular-weight compounds of biological origin.
The chemical defence system, consisting of biosensoring,
transmitting, and responsive elements, has been evolved,
starting from primitive eukaryotes and lower plants [5], to
protectmulticellular organisms against environmental chem-
ical insults (xenobiotics) and to maintain homeostasis of
endogenous low-molecular-weightmetabolites (endobiotics)
[6]. Being exposed to xenobiotic (drug) stress, an organism is
challenged to rapid and appropriate adaptation by activating
constitutive and expressing inducible systems, thus attenuat-
ing negative biological consequences. For this purpose, an
array of gene families and molecular pathways have been
developed during evolution to prevent cellular access, to
detoxify and eliminate toxins, and to repair chemical damage.
The active efflux proteins, for example, P-glycoproteins (P-
gp) [7], multidrug resistance (MDR) proteins [8], and multi-
xenobiotic resistance (MXR) proteins [9], directly eliminate
slightly lipophilic organic xenobiotics from cells serving as
the first line of chemical defence. Escaping the first-line
guardians, once in the cytoplasm, toxic nucleophilic com-
pounds undergo biotransformation by the oxidative phase
I enzymes (cytochrome P450 (CYP), flavoprotein monooxy-
genase, hemeoxygenase, amine oxidases, xanthine oxi-
dase, and others) to become electrophilic. The electrophile
is subjected to reductive or conjugative modification by
phase II enzymes (glutathione-S-transferases (GSTs), UDP-
glucuronosyltransferases (UGTs), catechol-O-methyl trans-
ferases (COMT), N-acetyl transferases (NATs), and many
others).
Reactive oxygen species (ROS) generated as by-products
of phase I reactions are rapidly reduced to nontoxic “physi-
ological” levels by antioxidant enzymes (superoxide dismu-
tases (SODs), catalase (CAT), glutathione peroxidases (GPx),
peroxiredoxins (PRx), and nonenzymatic antioxidants, such
as reduced glutathione (GSH), uric acid, ascorbic acid, and
ceruloplasmin, among others). All these constitutive protec-
tive systems are sufficient to cope with low levels of xenobi-
otics or endobiotics.The inducible chemical defence relies on
the array of stress responsive genes. In this case, chemical
stressors like anticancer chemotherapeutics should first be
recognised by specific sensors which, in turn, transmit alarm
signals to activate or express de novo transporting, biotrans-
forming, and detoxifying enzymes.
The primary member of mammalian proteins-sensors of
organic chemicals is the aryl hydrocarbon receptor (AhR),
activated by planar aromatic hydrocarbons of natural or
synthetic origin [10–12]. A second group of chemical sensors
comprises nuclear receptors, such as pregnane X, constitutive
androstane, peroxisome proliferators-activated, liver-X, and
farnesoid-X receptors, recognising a wide variety of xeno-
and endobiotics [12–14]. Nuclear factor erythroid-derived
2-related factors (Nrf1 and Nrf2) and related cap’n’collar-
(CNC-) basic leucine zipper proteins belong to another
family of sensors activated by oxidants and electrophiles
[15, 16]. Activation of such recognition elements after ligand
binding may result in alterations of ion channel conductivity,
kinase machinery, and cytoplasmic and nuclear transcription
factors, inducing cell response (signal transduction).
Signal transduction is oftenmediated by redox substances
(superoxide anion radical, hydrogen peroxide, lipid perox-
ides, aldehydes, and others) [17–21]. At moderate concentra-
tions, they are signals to start gene transcription via activation
of transcription factors (nuclear factor 𝜅B (NF-𝜅B), activator
protein 1 (AP-1), and antioxidant response element- (ARE-)
binding proteins) or initiating the protein kinase cascade [5,
16, 19].The latter pathway leads to the interactionwith specific
ARE of DNA motifs on promoters of antioxidant defence
enzymes such as GST, Mn-superoxide dismutase (MnSOD),
and glutamyl-cysteine ligase, among others [15].
Inherited or acquired alterations at any key point of the
chemical defence system might lead to chronic intoxication
and numerous human pathologies (chronic inflammation,
degeneration, carcinogenesis, multiple chemical sensitivity
syndrome, etc.) in the inherited or acquired MDR, respec-
tively (Figure 1). Usually, the course of anticancer chemo-
therapy induces the overexpression of drug transporters
MDR/MXR/P-gp [3, 4], activation of sensoring receptors,
electrophile/oxidant sensors, transcription factors, and over-
expression/activation of detoxifying/antioxidant enzymes [1].
Collectively, it causes rapid metabolism and elimination
of both the anticancer drugs and cytotoxic by-products
targeting tumour cells. Since the chemical defence system is
ubiquitous for all human organs and tissues and central to
organism functions, the attempts for its pharmacological sup-
pression in order to diminish MDR potentially bear the risk
of a multitude of undesired side effects. Upon the pharma-
cological interaction with components of universal chemical
defence system, the “good guy” evolved on purpose to protect
multicellular organisms from low-molecular-weight chemi-
cals could become a “bad guy” blocking desired therapeutical
effects of anticancer drugs (MDR).
On the grounds of our current knowledge, redox regu-
lation of multiple molecular pathways essential for human
chemical defence system can be implicated differentially in
normal host and in tumour cells. Owing to the fact that redox
balance in tumour cells is greatly altered as compared to
that of normal host cells [22, 23], selective redox inhibitors
targeting tumour-associated chemical defence as a cause of
MDR should be developed. Regarding potential health effects
of redox modulators on tumours, they are mainly attributed
to cancer chemoprevention, direct anticancer action (for
comprehensive review, see [23]), cancer sensitisation to con-
ventional chemotherapeutics, preferentially through MDR
suppression/reversal, cancer sensitisation to radio- and
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Figure 1: Inherited and acquired multiple drug resistance. (a) In the inherited multiple drug resistance (MDR), chronic exposure of
normal cells to low levels of unknown xenobiotics (XB) or/and endobiotics (EB) takes place. It causes upregulation of ATP-binding
cassette transporters such as P-glycoprotein (P-gp), MDR proteins (MDRs), and multiple xenobiotic resistance (MXR) without induction by
anticancer drugs. Single nucleotide polymorphisms of phase I and II metabolic enzymes and efflux transporters often accompany inherited
MDR and they could also be a causative reason for the resistance. Reactive oxygen species-mediated modulation of xenobiotics/drug
metabolism is similar to that in the acquired drug resistance. This cellular pattern seems to be associated with high risk of tumour
transformation. ROS: reactive oxygen species; MDR:multiple drug resistance transporters; MXR:multiple xenobiotic resistance transporters;
P-gp: P-glycoprotein; CYP: cytochrome P450; HO1: hemeoxygenase-1; SOD: superoxide dismutase; CAT: catalase; GPx: glutathione
peroxidase; PI3K: phosphatidylinositol-3 kinase; AhR: aromatic hydrocarbon receptor; NF-𝜅B: nuclear factor kappa B; AP-1: activator
protein 1; NR: nuclear receptor; Nrf2: nuclear factor erythroid-derived 2-related factor 2; ARE: antioxidant responsive elements. (b) In the
acquired MDR, chemotherapeutics induce redox-dependent MDR expression and activity in tumour cells. Chemotherapeutics activate also
aromatic hydrocarbon receptor- (AhR-) driven and ROS-regulated expression of transcriptional factors (nuclear factor kappa B (NF-𝜅B) and
activator protein 1 (AP-1)) which initiate inflammatory response. Reactive oxygen species (ROS) mediate activation of phosphoinositol-3
kinase upstream of inflammatory cytokine transcription and synthesis. ROS and AhR-associated stimulation of Nrf2 followed by antioxidant
responsive element of DNAmotif causes upregulation of protective, antioxidant, and detoxifying systems, such as antioxidant phase I and II
enzymes.
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Figure 2: Redox-active substances and cancer. A variety of redox-active substances (direct or indirect antioxidants) are known to exhibit
cancer chemopreventive properties. In the pharmacological anticancer protocols, redox-active agents could be used as direct anticancer
chemotherapeutics or synergies with cytotoxic effects of conventional anticancer drugs. Here, we discuss the feasibility of such substances in
suppression/reversal of acquired MDR. The redox agents are often used for the protection of normal tissues/organs against toxic effects of
chemotherapy and radiotherapy.
photodynamic therapies, and protection of normal host
organs/tissues against damage by chemo- and radiotherapy
(Figure 2).
This review will discuss existing and perspective possibil-
ities of differential targeted modulation of redox-dependent
components/pathways of intrinsic and induced chemical
defence as an emerging strategy for combinatory anticancer
therapies to overcome MDR. Molecular pathways-targets for
MDR attenuation or even reversal by redox-active substances
will be described in detail.
2. Intrinsic Multidrug Resistance
(MDR): Is It Possible to Overcome It by
Redox Modulation?
2.1. Inherited Overexpression of Drug Transporters Accelerates
Drug Efflux from Target Cells. Some individuals possess
the so-called intrinsic MDR having never been exposed to
chemotherapy. Genetical predisposition to resist xenobiotic
stress could, in principle, be explained in terms of single
nucleotide polymorphisms (SNPs) of complex MDR sys-
tem components, starting from drug transporters, censor-
ing receptors, and xenobiotic/drug metabolising enzymes
(see several examples below). On the other hand, a lead-
ing hypothesis indicates intrinsic MDR as a result of
chronic (“silent”) exposure to low-level xenobiotic stressors
or endogenous disturbances of lipid, glucose, and/or hor-
mone metabolism. Therefore, the molecular pathways of its
regulations are similar to those characteristic for acquired/
chemotherapy-induced MDR. In this line, the development
of intrinsic MDR correlates with increased risk of carcino-
genesis, and the process is under network-like redox control
(for comprehensive review, see [1]). It appears that the
classical paradigm of cancer chemoprevention with redox-
active nontoxic substances could be interpreted in terms of
intrinsic MDR prevention. Furthermore, intrinsic MDR is
a hallmark of stem cells, both normal and tumour, because
high resistance to any toxin would guarantee survival and
maintenance of stem cell populations.
2.2. Gene Polymorphisms Influencing Drug Metabolising
Enzymes May Result in Ultrafast Drug Elimination or
Extremely Slow Formation of Cytotoxic Redox By-Products.
The cytochrome P450 (CYP) system is a superfamily of
isozymes, located in the smooth endoplasmic reticulum,
mainly in the liver, but also in extrahepatic tissues (e.g.,
intestinalmucosa, lung, kidney, brain, lymphocytes, placenta,
and skin), involved in the biotransformation of numerous
lipophilic xenobiotics into more hydrophilic, less toxic, and
more easily excreted metabolites [11, 24, 25]. The major CYP
enzymes involved in human drug metabolism belong to fam-
ilies 1, 2, and 3, the specific drug metabolising isoforms being
Cyp1A2, Cyp2C9, Cyp2C19, Cyp2D6, and Cyp3A4/3A5.
Each CYP isoform is a product of specific gene. For some
isoforms, the existence of genetic polymorphisms has been
demonstrated. The allelic variants may be due to the deletion
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of the entire gene, SNPs, deletion or insertion of fragments of
DNA within the gene, or multiplication of gene copies, lead-
ing to absent, deficient, or enhanced enzyme activity. Thus,
the population can be classified into Extensive Metabolisers
(EM, individuals with normal capacity), Poor Metabolisers
(PM, individuals with reduced/null metabolic activity), and
Ultrarapid Metabolisers (UM, individuals with a higher-
than-normal metabolic activity). It seems that opposite pop-
ulations of PM and UM could be at risk of constitutive
MDR, because UM would rapidly metabolise/excrete parent
molecules of anticancer drugs, while PM would not produce
ROS as by-products of anticancer drug metabolism. These
by-products possess strong cytotoxicity against cancer cells.
Hence, the routine clinical diagnostics based on determina-
tion of CYP SNPs produce a reliable prediction of individual
chemosensitivity/chemoresistance/MDR to anticancer ther-
apies. Several polymorphisms have been connected with the
inducibility or enzymatic activity of the abovementioned
drug metabolising CYP isoforms [6].
2.3. Redox-Active Inhibitors of Drug Transporters and Recep-
tors Associated with Drug Detoxifying Enzymes: Hopes and
Reality. Notwithstanding the growing interest and great
hopes for natural nontoxic redox agents to prevent/inhibit/
reverse MDR ([26]; in this review), drug development
remains rather complicated due to low bioavailability, defined
by restricted absorption through intestine, lining epithelia,
and skin [24, 25], rapid metabolism, and excretion. Absorbed
MDR inhibitors become themselves targets for the classical
pathways of xenobiotic detoxification/drug metabolism [27–
29]. In phase I, they are predominantlymetabolised bymicro-
somal CYPs. Then, phase II glucuronidation by UGT [30],
sulfation by phenol and catecholamine specific sulfotrans-
ferases (SULT1A1 and SULT1A3) [11], methylation by COMT
[31], and binding with glutathione through GST occur [12,
28].
To improve candidate MDR inhibitor bioavailability and
attenuate its metabolic disruption, several approaches have
been implied such as injectable forms, other sophisticated
drug delivery systems, combinationwith adjuvants like piper-
ine and caffeine to diminish glucuronidation, and chem-
ical modification of parent molecules to bypass efficient
metabolic guardians [6, 24, 27].
A very high probability of drug-drug interactions
between the adjuvant therapeutics for MDR inhibition and
anticancer therapies themselves, as inducers of MDR, should
also be taken into consideration [32]. It has been reported
that potential MDR suppressors of herbal origin may easily
interact with the same efflux (P-gp) and metabolic (Cyp3A4)
pathways as anticancer agents do, resulting in opposite
outcomes: inhibition or expression of MDR components,
depending on timing, dosages, posology, and route of drug
administration [33]. Recent findings have shown that this
kind of drug-drug interaction is highly influenced by genetic
polymorphisms of efflux proteins (MDR1) and metabolic
enzymes (Cyp3A5) [34].
Emerging evidence shows that MDR could be an evolu-
tionary defined mechanism to preserve normal and cancer
stem cell populations. In this direction, redox signalling
becomes a probable candidate to maintain cell stemness
[1]. Therefore, the development of clinically efficient redox
modulators of MDR should selectively target cancer stem
cells, while leaving normal stem cells intact.
3. Redox Dependence of Acquired
Multidrug Resistance: Modulation by
Direct and Indirect Antioxidants
Most chemotherapeutic agents generate ROS, which bind to
specific structures within the cancer cells and promote cell
death. Chemotherapeutic agents disturb the redox homeosta-
sis in cells and change their ability to cope with excessive ROS
levels through the production of protective direct antioxi-
dants [35]. Direct antioxidants are modified in this process
and need to be resynthesised [36]. Glutathione (GSH) is con-
sidered as the main redox buffer in a cell because it supplies
large amounts (millimolar concentrations) of reducing equiv-
alents [37]. The intracellular thiol redox status is described as
the ratio of reduced to oxidised forms of thiols (GSH/GSSG),
which decreases under oxidative stress conditions, and GSH
reversibly forms mixed disulfide bonds between protein
thiols (S-glutathionylation) to prevent protein oxidation [38].
Besides GSH, thioredoxin (Trx), another important endoge-
nous antioxidant, provides protection against oxidative stress
[39, 40]. Nrf2 regulates Trx and sulfiredoxin enzymes, which
are involved in the regeneration of the reduced form of
nicotinamide adenine dinucleotide phosphate (NADPH) and
synthesis of GSH [41]. Among the potential mediators of
chemoresistance, Trx plays critical roles in the regulation of
cellular redox homeostasis and redox-regulated chemoresis-
tance [42–44].
In a recent study, Zhang et al. have shown that inhibiting
Nrf2 expression through the transfection of shRNA plasmids
in non-small-cell lung cancer cells significantly inhibited the
expressions of glutathione pathway genes, antioxidants, and
multidrug resistance proteins and induced the generation of
ROS, decreased the level of GSH, and inhibited cell prolifera-
tion [45]. It has been reported that diffuse large B lymphoma
cells expressed higher-than-normal basal levels of Trx, which
was associated with decreased survival. Suppressed Trx
inhibited cell growth and clonogenicity and sensitised the
lymphoma cells to doxorubicin [44]. In a recent study,
Raninga et al. [46] have reported the cytoprotective role of
tTrx1 and thioredoxin reductase 1 (TrxR1) enzyme inmultiple
myeloma. Trx inhibitors were utilised in a variety of human
cancers including acute myeloid leukemia [47], colorectal
cancer [48], and lung cancer [49] to inhibit tumour growth
and to stimulate ROS-induced apoptosis. Auranofin, a TrxR1
inhibitor, caused oxidative stress-induced cytotoxicity and
apoptosis in cancers including chronic myeloid leukemia
[50], chronic lymphocytic leukemia [51], prostate cancer [52],
and breast cancer [53]. Signal transducer and activator of
transcription 3 (STAT3) activation is commonly observed
in multiple myeloma, chronic lymphocytic leukemia, gas-
tric cancer, lung cancer, and laryngeal carcinoma. Dietary
gamma-tocotrienol inhibited both induced and constitutive
activation of STAT3 inmultiple myeloma and prostate cancer
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cell lines [54]. High-dose intravenous ascorbate inhibited
NADPH-oxidase and was selectively toxic to tumours with
low CAT activity [55]. Recent study has reported that a naph-
thoquinone derivative induced cell death depending on Bax
deficiency. In conclusion, it has been suggested that naphtho-
quinone might be clinically feasible to overcome chemoresis-
tance [56].
Plant-origin polyphenols or their synthetic derivatives
have been recognised as redox-active molecules with rel-
atively low toxicity. Some of them, for example, luteolin,
apigenin, and chrysin, exert both direct and indirect antiox-
idant effects by scavenging ROS and increasing Nrf2 activity,
followed by the induction of its target antioxidant genes
[57]. The natural polyphenols are also substrates for ABC
transporters as they bind to the active sites of the transporters
and reduce drug efflux [58].The prooxidant capacity of some
polyphenols (quercetin, epigallocatechin gallate) allowed
their identification as chemotherapeutic adjuvants since they
selectively enhanced cytotoxic effects of chemotherapeutics
[59]. Shin et al. have reported that some specific polyphenols
triggered cell cycle arrest and apoptotic cell death in cisplatin-
resistant A2780/Cis human ovarian cancer cells [60].
3.1. Antioxidant-Associated Modification of Drug Transport-
ing Systems. Elevated GSH levels trigger chemoresistance
by different pathways: direct interaction with drugs and
ROS, prevention of protein and DNA damage, and induc-
tion of DNA repair. For example, MRP1 causes efflux of
some xenobiotics (e.g., vincristine, daunorubicin) through
a cotransport mechanism with GSH [26, 61–63]. Oxidative
stress was more cytotoxic towards B16 melanoma cells with
low GSH concentrations [64]. Tumour cells overexpressing
𝛾-glutamyl-transpeptidase were more resistant to H
2
O
2
and
chemotherapeutics, such as doxorubicin, cisplatin, and 5-
fluorouracil [65]. GST-related chemoresistance modulated
protein-protein interactions with members of the mitogen-
activated protein (MAP) kinases including c-Jun N-terminal
kinase 1 and apoptosis signal-regulating kinase 1 and altered
balance of kinases during drug treatment [66]. This complex
mechanism involved the interaction of promoter regions for
GST andGGT withNF-𝜅B andNrf2 followed by upregulation
of several detoxification genes, such as ferritin, GSH-S-
reductase, and hemeoxygenase-1. Hypoxia induced breast
cancer resistance protein (BCRP) expression in tissues by
interacting with heme and porphyrins thus increasing levels
of cytoprotective protoporphyrins [67]. Overexpression of
BCRP is known to induce resistance to various chemother-
apeutic drugs, such as topotecan and methotrexate [68].
3.1.1. MDR Induction and Possibility to Inhibit It by Redox-
Active Substances Affecting Glutathione Metabolism. Definite
redox-active compounds, such as quinones, polyphenols,
oligomeric proanthocyanidins, ergothioneine, ovothiols, tan-
nins, or terpenes, behave as redox modulators and trigger
redox-related events, such as ROS increase and GSH deple-
tion, causing apoptosis of cancer cells [69]. In general, redox
modulations in cancer cells could initiate cell differentiation
or could induce apoptosis [70]. Acetaminophen, a widely
used drug to combat pregnancy-connected toxicity [71],
induced ROS production in human choriocarcinoma cells
by reducing BCRP and GSH content and activating Nrf2-
targeted genes:NAD(P)Hdehydrogenase, quinone 1 (NQO1),
and hemeoxygenase-1. On the other hand, genetic knockout
of TrxR1 gene resulted in liver insensitivity to acetaminophen
due to drastic disruption of the link between redox home-
ostasis and drug metabolism in the liver [72]. Glyoxalase 1,
a key enzyme converting 𝛼-oxoaldehydes into correspond-
ing 𝛼-hydroxy acids, has been found to be amplified in
many primary tumours and cancer cell lines [73]. In this
regard, Young et al. [73] have reported that overexpression
of both enzymes glyoxalase 1 and transglutaminase 2, an
enzyme catalysing polyamine conjugation/deamidation, led
to increased tumour cell survival, drug resistance, andmetas-
tasis [74]. The use of photodynamic anticancer therapy is
particularly attractive because of its specificity and selec-
tivity [75]. Hypericin, a naphthodianthrone, is a promising
photosensitizer, which is feasible for photodynamic therapy,
for fluorescence diagnosis, and for topical applications [76].
Mikesˇova´ et al. [77] have shown that hypericin content in
cells, GSH levels, and redox status correlated with hypericin-
induced photocytotoxicity. In contrast, resveratrol attenuated
cisplatin toxicity by maintaining GSH levels [78, 79]. It
has also been demonstrated that buthionine sulfoximine,
an inhibitor of GSH biosynthesis, increased the sensitivity
of the cells to chemotherapeutics, while N-acetyl cysteine
exhibited the reverse effect, particularly in drug-resistant cells
[61, 62, 80].Malabaricone-A, a diarylnonanoidwith a potency
of MDR reversal, induced depletion of GSH, inhibited
GPx activity, and caused redox imbalance [81]. Collectively,
molecular pathways-targets for MDR modulation by GSH
controlling agents are schematically presented in Figure 3.
3.1.2. Overexpression of ABC Transporters: Effects of NADPH-
Oxidase and CYP Inhibitors. NADPH-oxidase (NOX) is an
oxidoreductase and plays crucial roles in cell growth, pro-
liferation, and regulation of phosphatases and transcription
factors via redox-sensitive cysteine residues [82]. Elevated
NOX expression has been shown in breast cancer [83],
colon cancer [84], and neuroblastoma cells [85]. Barth et al.
have demonstrated that pharmacological block of glucosylce-
ramide synthase, a stimulator of NOX activity, substantially
improved cytotoxicity of chemotherapeutics in glioblastoma
cells [86]. The molecular mechanism of anticancer effects of
cisplatin involves activation of Akt/mTOR pathway regulated
by NOX-generated ROS, and NOX inhibition by diphenyl
iodonium was critical for cisplatin cytotoxicity [87].
Overexpression of the drug and xenobiotic metabolising
cytochrome P450 enzymes for a long time has been con-
sidered as one of the major mechanisms of chemoresistance
in solid tumours [88, 89]. Types 1 and 2 CYPs have been
proven to activate procarcinogens into ultimate carcinogens
[90]. CYPs have become therapeutic targets in anticancer
protocols amid their involvement in the activation and/or
inactivation of chemotherapeutic drugs [91]. Molina-Ortiz
et al. reported that altered CYP expression played a crucial
role in the therapy of Rhabdomyosarcoma patients [92]. The
in vitro antitumour action of natural product austocystin D
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Figure 3: Antioxidant and prooxidant systems as molecular targets for redox-active MDRmodulators. Glutathione and enzymes involved in
the glutathione metabolism such as glutathione reductase (GR) and glutathione peroxidase (Gpx) as well as gamma-glutamyl cysteine ligase,
catalase, NADPH-oxidase, thioredoxin (Trx), and peroxiredoxins (Prx) are potential molecular targets for future MDR modulators.
has been explained by selective activation of CYP enzymes
leading to DNA damage [93].
3.2. Chemotherapy-Induced Inflammatory Responses May
Cause Redox-Regulated Multidrug Chemoresistance. To
increase clinical efficacy of chemotherapy and combat MDR,
molecular and cellular processes promoting inflammation
have been targeted due to the common knowledge that
(i) inflammatory cells are present within tumours and (ii)
tumours arise at sites of chronic inflammation [94, 95].
Cancer promotion and progression stages are accelerated by
ROS generated by immune cells, mediators of inflammation
[96]. The induction of antioxidant defence enzymes in
tumours as an adaptation to oxidative attacks from host
immune cells might contribute to chemoresistance. Thus,
hydrogen peroxide-resistant thymic lymphoma cells with
increased catalase and total SOD activities, altered GSSG/
GSH redox potential, and oxidised NADP+/NADPH pool
exhibited resistance to conventional chemotherapeutics,
such as cyclophosphamide, doxorubicin, vincristine, and
glucocorticoids [97]. Chemotherapeutic agents caused
release of ATP into the extracellular space as they induced
tumour cell death [98]. Following accumulation of adenosine
in tumours through CD39 and CD73, immune responses
were suppressed [99]. Clayton et al. showed that exosome-
expressing CD39 and CD73 suppressed T cells through
adenosine production [100]. Oxidative stress has putative
impact on the activation and regulation of protein kinase
C (PKC) with redox-sensitive regions in both N-terminal
regulatory domain and C-terminal catalytic domain. Rimessi
et al. [101] have demonstrated that PKC𝜁 induced resistance to
apoptotic agents following its translocation into the nucleus
as a result of oxidative stress. Nuclear PKC𝜁 inhibitor restored
the apoptotic susceptibility of doxorubicin-resistant cells by
forming a complex with the proinflammatory transcription
factor NF-𝜅B and promoting IL-6 synthesis, thus favouring
tumorigenesis and MDR [102].
3.2.1. Activation of NF-𝜅B-Dependent Pathways and Their
Inhibition by Antioxidants. NF-𝜅B is the key transcription
factor involved in the inflammatory pathway. NF-𝜅B is
constitutively active in many of the signalling pathways
implicated in cancer. Hyperactivation of NF-𝜅B in can-
cer cells promotes cancer cell survival by inducing the
upregulation of antiapoptotic proteins such as MnSOD and
Bcl-2 family members and the inhibition of proapoptotic
proteins and is linked directly to the inflammation-induced
chemoresistance. NF-𝜅B protects against oxidative stress and
activates transcription factor c-myc, MMP gene expression,
and tumour angiogenesis and remodels extracellular matrix,
whileNF-𝜅B inhibition blocks cell proliferation [95, 103–106].
NF-𝜅B is associated with aberrant growth, resistance to apop-
tosis, and overexpression of the genes involved in cell cycle
promotion in cancer cells. In a recent study, it has been shown
that isorhamnetin, a metabolite of quercetin, enhanced
antitumour effects of chemotherapeutic drug capecitabine
through negative regulation NF-𝜅B [107]. Singh et al. have
reported that tea polyphenols inhibited cisplatin enhanced
activity of NF-𝜅B [108]. FADD-like IL-1beta-converting
enzyme inhibitory protein (FLIP) is a potent inhibitor of
caspase-8-mediated apoptosis involved in NF-𝜅B activation.
Talbott et al. revealed that FLIP regulates NF-𝜅B through
protein S-nitrosylation, a key posttranslational mechanism
controlling cell death and survival strategies [109]. Overex-
pression of cyclin D1 in cancer cells was reported in cisplatin
chemoresistance. In contrast, reduction of cyclin D1 expres-
sion resulted in the increased sensitivity to cisplatin due to
reducedNF-𝜅B activity and apoptosis [110]. It was shown that
vitamin E compounds, such as 𝛿- and 𝛾-tocotrienol, inhibited
NF-𝜅B activity, cell growth, cell survival, and tumour growth.
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In parallel, 𝛿-tocotrienol augmented sensitivity of pancreatic
cancer to gemcitabine [111].
Curcumin, a nontoxic food additive extensively used for
food flavouring [112], has been found to suppress human
hepatoma through inhibition of tumour cell proliferation, cell
cycle arrest in G2/M phase, and induction of apoptosis [113].
Numerous publications have reported curcumin as a sensi-
tiser for a number of anticancer drugs [114], first of all, cis-
platin [115]. Results of recent studies have also suggested that
curcumin was a reversal of induced MDR by multiple mech-
anisms such as the inhibition of ABC transporter expression
and function, activation of ATPase, and modulation of NF-
𝜅B activity during anticancer therapy [116]. In contrast,
caffeic acid, a natural phenolic, prevented antiproliferative
and proapoptotic effects induced by paclitaxel in lung cancer
cells by the activation of NF-𝜅B-survivin-Bcl-2 axis, thus
contributing to acquired MDR [117].
3.2.2. Activation of Phosphoinositol-3 Pathway and Its Inhibi-
tion in a Redox Fashion. The phosphatidylinositol-3 kinase
(PI3K) pathway has been widely considered to be associated
with oncogenesis, cancer progression, andmultiple hallmarks
ofmalignancy [118]. Consistently, PI3K pathway is a common
mechanism of resistance to antineoplastic agents [119]. Of
note, resistance to PI3K inhibitors may also develop due to
aberrant compensatory signalling through other pathways
[120]. The three main molecules in this pathway are PI3K,
Akt, and mammalian target of rapamycin (mTOR). Recently,
it has been reported that PI3K-mTOR inhibitor enhanced the
cytotoxicity of temozolomide, an advanced chemotherapy for
malignant gliomas [121].
Since activation of integrins, proteins expressed on the
cytoplasmic membrane of malignant cells, is controlled
directly by a redox site by disulfide exchange in their extracel-
lular domain, redox modifications of thiols could alter essen-
tial functions of integrins [122]. It was suggested that inactiva-
tion of VLA-4 integrin by nontoxic tellurium compound was
due to its binding to the thiol groups of cysteines that
decreased PI3K/Akt/Bcl-2 signalling while enhancing drug
sensitivity [123]. Gao et al. demonstrated that the natu-
ral bioflavonoid apigenin reversed drug-resistant pheno-
type by its suppressor effect on PI3K/Akt/Nrf2 pathway in
doxorubicin-resistant Nrf2 overexpressing cells [124].
3.2.3. Activation of Toll-Like Receptors (TLRs) by Chemother-
apeutics and Inhibitory Effects of Redox Modulators. Recent
studies implicate bacterial, parasitic, and viral infections as a
possible link between inflammation and carcinogenesis [125].
One possible redox-sensitive signalling pathway connect-
ing infection-associated inflammation and carcinogenesis is
mediated by Toll-like receptors (TLRs).The hypothesis is that
bacterial products, such as lipopolysaccharide, could activate
TLR4-MyD88 axis in tumour cells followedby the production
of proinflammatory cytokines, overexpression of antiapop-
totic signals (XIAP and pAkt), and, finally, acquisition of
chemoresistance by ovarian cancer cells [126]. Both in vivo
and in vitro experiments have shown that anticancer drug
paclitaxel exerted two opposite modes of action: killing of
breast cancer cells and enhancement of their survival through
activation of TLR4 pathway [127].The authors suggested that
simultaneous TLR4 block could reverse MDR to paclitaxel
and improve efficacy of the anticancer therapy.
Activation of TLRs in cancer cells seems to contribute
to the tumour growth, cancer cell survival, and MDR via a
signalling cascade involving cytokine/chemokine production
[128]. It was shown that ligation to the TLR2 in lung cancer
cells induced activation of mitogen-activated protein kinases
(MAPK) and NF-𝜅B, a classical pathway of survival strategy
[129]. Stimulation of TLR7/TLR8 in pancreas cancer cells
resulted in elevated NF-𝜅B and COX-2 expression, increased
cancer cell proliferation, and reduced chemosensitivity [130].
Active TLR-4/MyD88 signalling was also found in epithelial
ovarian cancer cells and influenced the drug response [131].
The relationships between the expressions of TLR-4, MyD88,
and NF-𝜅B have been examined in epithelial ovarian cancer
patients. Increased MyD88 expression was found to be
associated with poor survival rate [132].
3.3. Chemotherapy-Induced Redox-Dependent Stress Re-
sponses Leading to Adaptation. Along with killing cancer
cells, chemotherapeutic agents induce their stress and
adaptive responses. Signalling pathways and gene expression
in response to chemotherapeutics play pivotal roles in the
development of acquired MDR [133]. Key functional aspects
of cellular stress response include damage to membrane
lipids, proteins, and DNA and alterations in the redox status,
energy metabolism, cell cycle, and proliferation [134]. Thus,
there is clear-cut evidence that upregulation of nonenzymatic
and enzymatic antioxidant defence, molecular chaperones,
and stress responsive proteins are responsible for acquired
MDR [135]. These molecular pathways are potential targets
to enhance the cytotoxic effects of chemotherapeutics and to
overcome drug resistance.
3.3.1. Nrf2 as a Perspective Target to Overcome MDR in
Tumours. Nrf2, a redox-sensitive transcription factor, plays
a crucial role in redox homeostasis during oxidative stress.
Nrf2 is sequestered in cytosol by an inhibitory protein Keap1
causing its proteosomal degradation [136]. In response to
oxidative stress, Nrf2 translocates to nucleus and binds to
ARE that increases the expression of antioxidant genes such
as hemeoxygenase-1, NAD(P)H: quinone oxidoreductase 1,
aldo-keto reductases, and several ATP-dependent drug efflux
pumps [137]. Many genes involved in phase II metabolism
are also induced by Nrf2, including GSTs, UGT, and UDP-
glucuronic acid synthesis enzymes [138]. While Nrf2 upregu-
lation causes chemoresistance, its blockade sensitises a variety
of cancer cells, including neuroblastoma, breast, ovarian,
prostate, lung, and pancreatic cancer cells, to chemothera-
peutic drugs [139]. Several flavonoid compounds have been
reported to be potent Nrf2 inhibitors, such as epigallocat-
echin 3-gallate, luteolin, and brusatol [140, 141]. Nrf2 was
upregulated in hepatocellular carcinoma and positive corre-
lation was found between Nrf2 expression and antiapoptotic
Bcl-xL and MMP-9 [142]. Quercetin treatment increased
the total cellular amount and nuclear accumulation of Nrf2
protein in malignant mesothelioma cells [143]. In vitro
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suppression of Keap1 in human prostate and non-small-
cell lung carcinoma cell lines elevated Nrf2 activity and
increased sensitisation to various chemotherapeutic agents
and radiotherapy [144, 145]. These results demonstrated that
Nrf2 inhibitors are effective adjuvants of chemotherapeutic
drugs.
3.4. Chemotherapy-Induced Prosurvival and Antiapoptotic
Cellular Strategies: Roles for Anti- and Prooxidants. Cellular
redox homeostasis is maintained by the balance between
endogenous antioxidant defence system, including antiox-
idant enzymes such as SOD, catalase (CAT), GPX, GSH,
proteins, and low-molecular-weight scavengers, such as uric
acid, coenzyme Q, and lipoic acid, and the prooxidant
molecules, leading to the formation of several highly oxidis-
ing derivatives.
3.4.1. p53 Proapoptotic Protein. p53 is considered as the
guardian of the genome, and several genemutations encoding
p53 have been detected in several tumour cells. Under
physiological conditions, activated p53 plays a key role in
tumour prevention by promoting synthesis of antioxidant
enzymes. ROS-induced DNA damage activates p53, leading
to apoptosis via the mitochondrial intrinsic pathway and
increasing the synthesis of prooxidant enzymes. Since p53 is
a redox-sensitive factor, ROS negativelymodulates its activity
via oxidative modification of the cysteine residues at the
DNA-binding site. It has been proposed that the loss of p53
function in cancer cells is associatedwith their ability to avoid
apoptosis [146]. Mutations of p53 are involved in resistance to
chemotherapy [147]. It was demonstrated that p53 regulated
Nrf2 negatively and interfered with the ability of Nrf2 to bind
to DNA. A low level of p53 favoured binding of Nrf2 to DNA.
In a recent study, the treatment with bortezomib, which is
a selective proteasome inhibitor, induced Myelocytomatosis
Viral OncogeneNeuroblastoma (MYCN) downregulated p53
expression, leading to cell survival in neuroblastoma [148].
3.4.2. Bcl-2 Antiapoptotic Protein. Bcl-2 protein is a member
of a family of apoptosis-modulating proteins which pro-
tects against a variety of apoptotic stimuli, mainly acting
at the mitochondrial level. In addition to its antiapoptotic
action, Bcl-2 has been shown to exert potent antioxidant
effects [149] such as protection of lipid membranes against
peroxidation reactions, maintenance of cellular redox status
(i.e., NADH/NAD+ and GSH/GSSG in a reduced state) in
response to oxidative stress [150], and elevation of cellular
levels of glutathione and reducing equivalents [151]. Bcl-2
upregulates antioxidant defence systems, and its mitochon-
drial localisation contributes to achieving this effect. Bcl-2 is
capable of forming ion channels as a regulator of mitochon-
drial permeability transition [152]. Mitochondrial permeabil-
ity transition blockade prevents release of cytochrome c, an
apoptosis initiating factor. Herrmann et al. reported that Bcl-
2 selectively regulates nuclear localisation of cell death reg-
ulators such as p53 and NF-𝜅B [153]. Cellular redox state via
thiols plays amajor role in regulatingmitochondria-mediated
events during apoptosis, and oxidation of mitochondrial
thiols is an apoptotic sensor. GSH is involved in detoxifying
reactions and it has a high intracellular concentration. It
serves as the major reducing peptide within all of the cells,
due to its sulfhydryl group buffering and removing free radi-
cals generated duringmetabolic processes such as respiration.
GSH is an important factor for Bcl-2 ability to suppress
apoptosis. Chaiswing et al. observed that thiol redox status
and activities and expression of several antioxidant enzymes
exhibited distinct patterns in two prostate cancer cell lines
at different growth phases, suggesting that modulation of
thiol redox status might be useful as a therapeutic tool to
modify cancer cell proliferation and tumour aggressiveness
[154]. Mitochondrial metabolism is altered in malignant cells
so that, in contrast to normal or benign cells, malignant
cells accumulate citrate due to low activity of mitochondrial
aconitase, become citrate-oxidising cells, and exhibit low
amounts of citrate.The higher rate ofmitochondrial substrate
metabolism explains the increased levels of ROS associated
with malignancy and metastasis. The foregoing discussion
illustrates the importance of GSH in mitochondrial function
and redox status, in determining the metastatic aggressive-
ness and sensitivity of cancer cells to chemotherapeutic
agents, and provides the rationale for mitochondrial GSH as
a potential therapeutic target in cancer [155].
3.5. Chemotherapy-Induced Transcription and Activity of Aro-
matic Hydrocarbons (Ah) Receptor. AhR is a basic helix-loop-
helix transcription factor that, prior to ligand binding, is
stabilised in the cytoplasm by direct interaction with several
proteins such as heat shock protein 90, its cochaperon, and
X-associated protein 2. Upon binding to aromatic ligands,
toxins, drugs, phytochemicals, and sterols, the AhR-ligand
complex shuttles from cytoplasm to the nucleus, where it
heteromerises with the AhR nuclear translocator (Arnt) to
form the transcription complex able to bind to xenobiotic
responsive elements (XRE) DNA-binding motifs located in
the promoter region of the target drug metabolising genes,
such as phase I (mainly, Cyp1 subfamily) and II metabolising
enzymes and Nrf2 [156–158]. One of the downstream targets
for AhR is BCRP encoded by ABCC3 gene [159–161]. The
coordinate AhR- and Nrf2-dependent transcriptional regula-
tion of humanUGTs by utilising bothXRE- andARE-binding
motifs takes place to protect cells from xenobiotic and oxida-
tive stresses [162].The elegant studywith geneticallymodified
mice has clearly demonstrated that Nrf2 is required for
ligand-associated induction of classical “AhR battery” genes
NQO1, GST isoforms, and UGTs [163]. Apart frommetabolic
enzymes, a number of growth factors, cytokines, chemokines,
and their receptors are downstream gene targets for activated
AhR [164, 165]. AhR is also functionally connected with epi-
dermal growth factor receptor, presumably, through NF-𝜅B-
regulated pathway [166], thus influencing the epithelial cell
proliferation. AhR can also cross-talk and directly interact
with proteins involved in major redox-regulated signalling
pathways such as NF-𝜅B and various kinases such as Src,
JNK, p38, and MAPK [167] and with oestrogen receptors
to mediate oestrogen metabolism [168, 169]. Recent studies
have unraveled unsuspected physiological roles and novel
alternative ligand-specific pathways for this receptor that
allowed hypothesising numerous pharmacological roles of
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AhR ligands useful for the development of a new generation
of anti-inflammatory and anticancer drugs [159, 170].
The AhR-mediated regulation of aromatic hydrocarbons
metabolism has been implicated in a variety of cancers [164,
171] affecting different stages of carcinogenesis. If metabolic
activation of the organic molecules increased the levels of
their adducts with DNA thus promoting cancer initiation,
anticancer drug- or toxin-induced AhR activation played
a pivotal role in cancer promotion and progression [172,
173]. Elevated AhR expression associated with constitutive
nonligand activation has been found in several cancers as
evidenced by the nuclear localisation of AhR and induced
downstream gene Cyp1A1 [174, 175]. Stable knockdown of
AhR decreased the tumorigenic and metastatic properties of
breast cancer cell line in vitro and in vivo. On the other hand,
AhR overexpression in nontumour humanmammary epithe-
lial cells transformed them in cells withmalignant phenotype
[176]. Of importance, AhR knockdown downregulated the
expression of ABCC3; overexpression of this gene in breast
cancer has been strongly associated with acquired MDR
[177] and resistance to paclitaxel, a drug widely used in the
treatment of metastatic breast cancer [178]. Inherited poly-
morphisms inAhR, for example, substitutionArg554Lys, and
its machinery [179, 180] or presence of endogenous ligands-
stimulators for the receptor (cAMP, bilirubin, prostaglandins,
oxidative lipids, etc.) could be implicated into inherited
MDR.
To suppress AhR transcription pharmacologically several
approaches have been proposed, including the modulation
of protein-protein interaction between transcription factor,
coactivators, and corepressors [160, 167, 181]. A number of
dietary polyphenols with redox properties (resveratrol, quer-
cetin, curcumin, etc.), indoles, tryptophane metabolites,
bilirubin, and oxidised products of lipid metabolism have
been suggested as nontoxic ligands-activators or ligands-
inhibitors of AhR expression by competitive and noncom-
petitive pathways [181, 182]. If ligands-activators of AhR are
regarded as potential anti-inflammatory agents [181–184],
redox-active ligands able to suppress AhR expression/
functions could be candidates for MDR reversals. For
example, 7-ketocholesterol, a major dietary oxysterol, may
actually strongly inhibit AhR activation [185]. Alpha-
naphthoflavone is considered as a classical AhR antagonist
blocking activation of XRE-containing reporter gene and
Cyp1 upregulation in hepatoma cells [186]. However, alpha-
naphthoflavone is also a partial agonist of AhR and acts as a
competitive inhibitor exclusively in the presence of another
agonist. Recently, more selective pure ligands-antagonists of
AhR have been developed such as 2-methyl-2H-pyrazole-3-
carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide, 3󸀠-
methoxy-4󸀠-nitroflavone, 3󸀠,4󸀠-dimethoxyflavone, and 6,2󸀠,
4󸀠-trimethoxyflavone.These were able to block the induction
of Cyp1A1-dependent ethoxyresorufin O-deethylase (EROD)
activity [187–190]. They all belong to redox-active flavones
and after proper clinical studies on safety and efficacy could
be feasible for combinatory anticancer therapy to combat
MDR. Among a number of plant polyphenols used for topical
application, exclusively the phenylpropanoid verbascoside
and flavonoid quercetin proved to be strong inhibitors of
UV- or FICZ-upregulated AhR-Cyp1A1-Cyp1B1 axis in
human keratinocytes [184], suggesting their potency as
topical MDR suppressors/reversals.
4. Conclusions
The multiple pleiotropic interactions of redox-active
molecules so far demonstrated on the molecular pathways
controlling cellular MDR, from xenobiotic cellular uptake
inhibition to the modulation of phase I/II enzyme
detoxification, to the inhibition of Toll-like receptor
activation and/or AhR expression and function, provide a
consistent rationale for the necessity of more intense and
systematic research efforts in the field of anti-/prooxidant
adjuvants for anticancer chemotherapy, to attempt clinically
effective MDR inhibition with tolerable toxicity.
The design and implementation of more selected and
targeted clinical studies centred on redox-active candidate
MDR-interfering molecules will possibly contribute to over-
coming the presently dominating clinical practice, which
confers a constantly growing interest in redox modulators
and antioxidants as a mere palliative against the potent
cytotoxicity of conventional and biologic anticancer drugs.
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